VARIATION OF LIFE QUALITY AND SOCIAL FUNCTIONING INDICATION IN PATIENTS WITH SCHIZOPHRENIA ACCORDING TO TREATMENT RESPONSE
Abstract
Background: To conduct a comparative analysis of indicators of life quality and social functioning in patients with schizophrenia according to the received treatment.
Materials and methods: The study involved 105 patients with paranoid schizophrenia between 18 and 55 years, who were randomly assigned to 3 groups. The first group included 35 patients treated with sertindole (average therapeutic dose of 18,0 cu chlorpromazine equivalents), the second – 35 patients treated with zuclopenthixol (4,0 arbitrary units), and a third – 35 patients treated with clozapine (2,0 contingent units). The rehabilitation included individual therapy compliance. All patients signed informed consent to participate in the study.
The study included the use of outpatient and inpatient patient cards and a questionnaire for the assessment of life quality and social functioning of the psychic patients.
Statistical data processing was carried out using the software package «Statistica 6.0».
Results: Summarizing the results, we can conclude a significance of the subjective assessment of the life quality in the responses of patients with schizophrenia to questions during a questionnaire for determining the level of life quality and social functioning.
In the study of the variability of indicators of life quality and social functioning of patients with schizophrenia, depending on the treatment, all parameters throughout the course of therapy were higher in the group of patients treated with sertindole.
Conclusion: Thus, sertindole is the drug of choice for long-term outpatient treatment of patients with schizophrenia, particularly in combination with compliance – therapy.
Full Text:
>PDF
References
Altynbekov K.N. Farmakojekonomicheskie aspekty terapii shizofrenii [Pharmaeconomic aspects of schizophrenia treatment]. Rossijskij psihiatricheskij zhurnal [Russian Psychiatric Journal], 2014, no. 6, pp. 51–55.
Babin S.M., Shlafer A.M., Sergeeva N.A. Komplaens – terapiya bol’nykh shizofreniey [Compliance – therapy of schizophrenia patients]. Meditsinskaya psikhologiya v Rossii [Medical psychology in Russia] 2011. N2. http://medpsy.ru (accessed: 30.03.2016)
Gurovich I.Ja., Shmukler A.B. Oprosnik dlja ocenki social’nogo funkcionirovanija i kachestva zhizni psihicheski bol’nyh [Questionnaire for social functioning and life quality od psychic patients assesment]. Social’naja i klinicheskaja psihiatrija [Social and clinical psychiatry], 1998, iss. 8, no. 2, pp. 35–40.
Kir’yanova E.M., Sal’nikova L.I. Sotsial’noe funktsionirovanie i kachestvo zhizni psikhicheski bol’nykh – vazhneyshiy pokazatel’ effektivnosti psikhiatricheskoy pomoshchi [Social functioning and life quality of psychic patients as the most important indicator of psychiatric help]. Sotsial’naya i klinicheskaya psikhiatriya [Social and clinical psychiatry], 2010, iss. 3, no. 20, pp. 73–75.
Kozhina A.M., Gaychuk L.M. Opyt primeneniya preparata soleron v terapii shizofrenii [Experience of soleron treatment in schizophrenia therapy]. Ukraїns’kiy vіsnik psikhonevrologії [Ukraine ambassador of psychotherapy], 2010, iss. 18, no. 4, pp. 116–117.
Krasnov V.N., Gurovich I.Ya., Mosolov S.N., Shmukler A.B. Psikhiatricheskaya pomoshch’ bol’nym shizofreniey [Psychiatric help to schizophrenic patients]. Klinicheskoe rukovodstvo [Clinical guidelines]. M.: Medpraktika, 2007. 260 p.
Maslovskiy S.Yu., Kozlovskiy V.L. Izmerenie kachestva zhizni bol’nykh shizofreniey pri provedenii podderzhivayushchey terapii [Life quality of schizophrenic patients’ measurement during maintenance therapy]. Obozrenie psikhiatrii i meditsinskoy psikhologii [Psychiatry and medical psychology review], 2009, no. 3, pp. 29–31.
Orudzhev N.Ja., Mozharov N.S. Aripiprazol (amdoal): atipichnyj nejroleptik pri lechenii shizofrenii [Aripiprazol (amdoal): atypical neuroleptic in schizophrenia treatment]. Lekarstvennyj vestnik [Drug ambassador], 2014, no.2 (54), iss. 8, pp. 30–33.
Savel’eva O.V. Kriterii ocenki jeffektivnosti reabilitacii bol’nyh paranoidnoj shizofreniej v ambulatornoj praktike [The assesment criteria of rehabilitation of outpatients with paranoid schizophrenia]. Prakticheskaja medicina [Practical Medicine], 2014, no. 2 (78), pp. 83–88.
Tarakanova E.A., Kozhanov A.V. Sovremennaja psihofarmakoterapija pri shizofrenii: sohranenie zhizni bol’nyh [Modern psychoparmacy of schizophrenia: saving of patients life]. Vestnik akademii znanii [Ambassador of knowledge academy], 2015, no. 12 (1). http://ores.su/ru/journals/vestnik-akademii-znanij/2015-nomer-12-1-statej-17/a210667 (accessed: 30.03.2016).
Shemet V.A., Karpjuk V.A. Osobennosti jemocional’nogo intellekta, kachestva zhizni i social’nogo funkcionirovanija u pacientov s shizofreniej [Features of emotional intelligence, quality of life and social functioning of patients with schizophrenia]. Vestnik psihiatrii i psihologii Chuvashii [Ambassador of psychiatry and narcology of Chuvashiya]. 2012, no. 8. http://cyberleninka.ru/article/n/osobennosti-emotsionalnogo-intellekta-kachestva-zhizni-i sotsialnogo-funktsionirovaniya-u-patsientov-s-shizofreniey (accessed: 22.06.2016).
Azorin J-M., Murteira S., Hansen K. et al. Evaluation of patients on sertindole treatment after failure of other antipsychotics: a retrospective analysis. BMC Psychiatry. 2008. Vol. 8. № 16.
Bobes J., Garcia-Portilla M.P., Bascaran M.T., Saiz P.A., Bouzoño M. Quality of life in schizophrenic patients. Dialogues in Clinical Neuroscience. 2007; 9 (2): 215–226.
Browne S, Roe M, Lane A, et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand. 1996; 94: 118–124.
Gallhofer B, Jaanson P, Mittoux A et al. Course of recovery of cognitive impairment in patients with schizophrenia: a randomized double-blind study comparing sertindole and haloperidol. Pharmacopsychiatry. 2007. Vol. 40, рр. 275–288.
Hansen K., Sapin C., Toumi M. Sertindole in the treatment of schizophrenia in Poland: a cost analysis. Poster presented at the 10th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Dublin, Ireland, 20–23 October, 2007.
Lehman A.F. The well-being of chronic mental patients: assessing their quality of life. Arch Gen Psychiatry. 1983; 40: 369–373.
Mahlum E., Hansen K., Sapin C. Pharmacoeconomic positioning of sertindole among antipsychotics in the management of schizophrenia in Norway. Presented at the 11th Annual European Congress of the International Society for Pharmacoeconomics and Outcome Research (ISPOR). Athens, Greece, 8–11 November 2008.
Skantze K., Malm U., Dencker S.J., May P.R., Corrigan P. Comparison of quality of life with standard of living in schizophrenic outpatients. Br J Psychiatry. 1992; 161: 797–801.
Refbacks
- There are currently no refbacks.
Copyright (c) 2018 Russian Journal of Medicine and Public Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.